Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis.
Emilie Kristine DahlOsama Karim AbedJens KjeldsenMarco DoniaInge Marie SvaneAnders DigeJørgen Steen AgnholtJacob Tveiten BjerrumJakob Benedict SeidelinPublished in: Alimentary pharmacology & therapeutics (2022)
Infliximab led to complete resolution of symptoms in 73% of patients with IMC. High prednisolone dose at tapering was associated with increased mortality rate and a high incidence of infections and hospitalisations in patients with severe IMC. We suggest optimised infliximab treatment before escalation of steroid doses.